Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Rises By 275.0%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 427,500 shares, a growth of 275.0% from the December 31st total of 114,000 shares. Based on an average trading volume of 184,800 shares, the short-interest ratio is currently 2.3 days. Approximately 4.5% of the company’s stock are short sold.

bioAffinity Technologies Stock Performance

Shares of BIAF stock traded down $0.01 on Thursday, hitting $0.77. 50,438 shares of the stock traded hands, compared to its average volume of 310,660. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. bioAffinity Technologies has a 1-year low of $0.57 and a 1-year high of $3.62. The company’s fifty day moving average is $0.94 and its 200 day moving average is $1.49. The company has a market capitalization of $12.08 million, a PE ratio of -0.94 and a beta of 2.98.

Institutional Trading of bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC lifted its position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned approximately 0.30% of bioAffinity Technologies worth $42,000 at the end of the most recent reporting period. 1.64% of the stock is currently owned by institutional investors and hedge funds.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.